CVAC Stock Summary and Trading Ideas (Curevac N.V. - | NASDAQ:CVAC)

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Curevac N.V. - trades on the NASDAQ stock market under the symbol CVAC.

As of December 5, 2025, CVAC stock price was flat at $5.12 with 230,295 million shares trading.

CVAC has a beta of 1.23, meaning it tends to be more sensitive to market movements. CVAC has a correlation of 0.17 to the broad based SPY ETF.

CVAC has a market cap of $1.15 billion. This is considered a Small Cap stock.

Last quarter Curevac N.V. - reported $63 million in Revenue and $1.41 earnings per share. This beat revenue expectation by $49 million and exceeded earnings estimates by $1.58.

In the last 3 years, CVAC traded as high as $12.79 and as low as $2.22.

The top ETF exchange traded funds that CVAC belongs to (by Net Assets): IBB, ONEQ, GWX, SPDW, GNOM.

CVAC has outperformed the market in the last year with a return of +77.2%, while the SPY ETF gained +13.9%. However, in the most recent history, CVAC shares have underperformed the stock market with its stock returning -4.3% in the last 3 month period and 0.0% for the last 2 week period, while SPY has returned +5.8% and +5.0%, respectively.

CVAC support price is $5.04 and resistance is $5.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CVAC shares will trade within this expected range on the day.